Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Spain: These 57 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Spain: These 57 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZTALMY (ganaxolone) generic drug versions launch in Spain?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Spain Patent 2,812,250

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Spain?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Spain Patent 2,524,009

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can LETAIRIS (ambrisentan) generic drug versions launch in Spain?

Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Spain Patent 2,544,724

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. Additional details are available on the ambrisentan profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Spain?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Spain Patent 2,625,083

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Spain?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Spain Patent 2,461,315

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in Spain?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Spain Patent 2,374,963

VYKAT XR is a drug marketed by Soleno. There are six patents protecting this drug. There has been litigation on patents covering VYKAT XR

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can VYKAT XR (diazoxide choline) generic drug versions launch in Spain?

Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: Spain Patent 2,984,297

VYKAT XR is a drug marketed by Soleno. There are six patents protecting this drug. There has been litigation on patents covering VYKAT XR

The generic ingredient in VYKAT XR is diazoxide choline. Additional details are available on the diazoxide choline profile page.

When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Spain?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Spain Patent 2,701,725

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Spain?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Spain Patent 2,403,206

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Spain?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Spain Patent 2,761,180

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Spain?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Spain Patent 2,763,829

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can NESINA (alogliptin benzoate) generic drug versions launch in Spain?

Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Spain Patent 2,639,854

Drug Price Trends for NESINA
NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. Additional details are available on the alogliptin benzoate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Spain?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Spain Patent 2,354,397

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Spain?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Spain Patent 2,674,681

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Spain?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Spain Patent 2,674,681

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can VANFLYTA (quizartinib dihydrochloride) generic drug versions launch in Spain?

Generic name: quizartinib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2027
Generic Entry Controlled by: Spain Patent 2,422,890

VANFLYTA is a drug marketed by Daiichi Sankyo Inc. There are eleven patents protecting this drug.

See drug price trends for VANFLYTA.

The generic ingredient in VANFLYTA is quizartinib dihydrochloride. Additional details are available on the quizartinib dihydrochloride profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Spain?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Spain Patent 2,375,503

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Spain?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Spain Patent 2,620,459

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Spain?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Spain Patent 2,743,784

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can BYSANTI (milsaperidone) generic drug versions launch in Spain?

Generic name: milsaperidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Spain Patent 2,542,967

BYSANTI is a drug marketed by Vanda Pharms Inc. There are ten patents protecting this drug. There has been litigation on patents covering BYSANTI

The generic ingredient in BYSANTI is milsaperidone. Additional details are available on the milsaperidone profile page.

When can INLYTA (axitinib) generic drug versions launch in Spain?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Spain Patent 2,634,866

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can INLYTA (axitinib) generic drug versions launch in Spain?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Spain Patent 2,919,351

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Spain Patent 2,554,353

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Spain Patent 2,580,803

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Spain Patent 2,659,364

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Spain Patent 2,882,684

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Spain?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Spain Patent 2,404,818

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Spain?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Spain Patent 2,565,179

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Spain?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Spain Patent 2,981,985

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Spain?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Spain Patent 3,073,615

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Spain?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Spain Patent 2,555,515

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Spain?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Spain Patent 2,628,025

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Spain?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Spain Patent 2,761,227

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch in Spain?

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2027
Generic Entry Controlled by: Spain Patent 2,749,800

CONTRAVE is a drug marketed by Azurity. There are eighteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Spain?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Spain Patent 2,611,020

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Spain?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Spain Patent 2,694,401

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Spain?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Spain Patent 2,611,020

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Spain?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Spain Patent 2,694,401

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Spain?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Spain Patent 2,467,665

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Spain?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Spain Patent 2,575,797

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Spain?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Spain Patent 2,714,092

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Spain?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Spain Patent 2,903,444

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch in Spain?

Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 15, 2027
Generic Entry Controlled by: Spain Patent 2,379,200

Drug Price Trends for TRINTELLIX
TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. Additional details are available on the vortioxetine hydrobromide profile page.

When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch in Spain?

Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 15, 2027
Generic Entry Controlled by: Spain Patent 2,432,102

Drug Price Trends for TRINTELLIX
TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. Additional details are available on the vortioxetine hydrobromide profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Spain?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Spain Patent 2,550,504

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Spain?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Spain Patent 2,498,047

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Spain?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Spain Patent 2,352,360

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Spain?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Spain Patent 2,423,951

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Spain?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Spain Patent 2,423,951

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Spain?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Spain Patent 2,526,352

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Spain?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Spain Patent 2,614,283

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Spain?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Spain Patent 2,603,879

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch in Spain?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Spain Patent 2,383,713

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can TRIFERIC AVNU (ferric pyrophosphate citrate) generic drug versions launch in Spain?

Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Spain Patent 2,383,713

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. Additional details are available on the ferric pyrophosphate citrate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Spain?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Spain Patent 3,032,244

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Spain?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Spain Patent 2,462,946

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Spain?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Spain Patent 2,732,326

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch in Spain?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 09, 2027
Generic Entry Controlled by: Spain Patent 2,662,590

Drug Price Trends for DAKLINZA
DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. Additional details are available on the daclatasvir dihydrochloride profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Spain?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Spain Patent 2,768,224

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch in Spain?

Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 17, 2027
Generic Entry Controlled by: Spain Patent 3,030,116

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. Additional details are available on the gallium ga-68 gozetotide profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Spain?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Spain Patent 2,625,930

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 2,612,331

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 2,908,719

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 2,950,337

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 2,951,457

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Spain?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Spain Patent 3,070,394

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Spain?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Spain Patent 2,559,528

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Spain?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Spain Patent 2,613,936

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Spain?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Spain Patent 2,513,390

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Spain?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Spain Patent 2,513,390

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Spain?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2027
Generic Entry Controlled by: Spain Patent 2,387,923

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in Spain?

Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2027
Generic Entry Controlled by: Spain Patent 2,439,581

Drug Price Trends for ZUBSOLV
ZUBSOLV is a drug marketed by Edenbridge Pharms. There are ten patents protecting this drug and four Paragraph IV challenges. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering ZUBSOLV

See drug price trends for ZUBSOLV.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Spain?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Spain Patent 2,572,189

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Spain Patent 2,611,077

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Spain Patent 2,790,830

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Spain?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Spain Patent 2,993,060

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Spain?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Spain Patent 2,562,775

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Spain?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Spain Patent 2,856,871

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can ONPATTRO (patisiran sodium) generic drug versions launch in Spain?

Generic name: patisiran sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 27, 2027
Generic Entry Controlled by: Spain Patent 2,638,448

ONPATTRO is a drug marketed by Alnylam Pharms Inc. There are thirteen patents protecting this drug. There has been litigation on patents covering ONPATTRO

See drug price trends for ONPATTRO.

The generic ingredient in ONPATTRO is patisiran sodium. Additional details are available on the patisiran sodium profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in Spain?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: Spain Patent 2,804,348

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

Spain Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risk, and Commercial Outlook

Last updated: October 12, 2026

Spain is a large, price-regulated European pharmaceutical market with strong public-payer influence, regional procurement, high generic substitution in many therapeutic areas, and growing biosimilar adoption. Branded medicines retain significant commercial protection through patents, regulatory exclusivity, hospital procurement positions, and differentiated formulations. Generic and biosimilar companies have opportunities in off-patent small molecules, hospital tenders, complex products, shortages, and localized supply, but face aggressive price controls, autonomous-community fragmentation, reference pricing, and delayed market access.

What is the size and structure of Spain's pharmaceutical market?

Spain has two principal pharmaceutical channels:

Channel Main buyers Commercial characteristics
Community pharmacy Spanish National Health System, patients, private insurers Prescription reimbursement, reference pricing, pharmacy dispensing
Hospital and institutional Autonomous communities, public hospitals, private hospitals Centralized and regional tenders, hospital formularies, negotiated discounts

The Spanish National Health System, or SNS, is the dominant payer for prescription medicines. Spain's 17 autonomous communities manage most healthcare delivery and procurement, creating regional differences in formulary access, tender design, prescribing policy, and adoption speed.

Retail prescription medicines are subject to national reimbursement and pricing decisions, but practical access also depends on regional and local implementation. Hospital medicines are often negotiated through tenders that can select one or several suppliers for a defined period.

The branded market includes originator products, patent-protected medicines, differentiated formulations, hospital brands, and off-patent branded products that continue to sell under a trade name. The generic market includes branded generics, unbranded generics, authorized generic products, and products marketed by Spanish and international manufacturers.

How large is the Spanish generic drug market?

Generics represent a substantial share of prescription volume in Spain, but their value share is lower because Spanish reimbursement and reference-pricing rules compress prices. Industry and market-research estimates generally place generic penetration near or above 40% of prescription units in recent years, with materially lower value penetration. The exact percentage varies by source, channel, product definition, and whether biosimilars are included.

Generic uptake is highest where:

  • The reference product has lost exclusivity.
  • The active ingredient has several suppliers.
  • The medicine is dispensed through community pharmacies.
  • Regional prescribing policies favor substitution or lower-cost alternatives.
  • Hospital tenders have produced multi-supplier or single-winner awards.

Generic penetration is weaker in certain specialties where physicians prefer established brands, patients use hospital channels, supply is concentrated, or the product has complex delivery or manufacturing requirements.

The commercial consequence is clear: Spain can offer high unit volume but modest net pricing. A generic launch requires scale, efficient procurement, reliable supply, and a cost base that can withstand repeated price reductions.

What regulatory pathway applies to generic medicines in Spain?

A generic medicine can enter Spain through national, decentralized, mutual-recognition, or centralized European procedures, depending on the product and legal requirements.

National and European authorization routes

The principal routes are:

  1. National procedure. Spain is the reference member state or the application is limited to Spain.
  2. Mutual-recognition procedure. An existing national authorization is recognized in other European Union member states.
  3. Decentralized procedure. Spain and other EU states assess an application simultaneously where no authorization exists.
  4. Centralized procedure. The European Medicines Agency and European Commission grant a single authorization valid across the EU. This route is mandatory for certain biotechnology medicines and other categories.

The Spanish Agency for Medicines and Medical Devices, AEMPS, is responsible for national regulatory implementation, pharmacovigilance, manufacturing oversight, inspections, shortages, and market supervision. AEMPS maintains the CIMA medicines database, which provides public information on authorized medicines and product characteristics. Spain does not operate a US-style Orange Book.

A generic application generally relies on the reference medicine's prior safety and efficacy data and must demonstrate pharmaceutical equivalence and bioequivalence, subject to applicable exceptions. The product must comply with EU good manufacturing practice, pharmacovigilance, serialization, labeling, and packaging requirements.

When can a generic medicine launch in Spain?

A generic launch depends on the expiry or successful invalidation of relevant patent rights, regulatory exclusivity, regulatory approval, pricing and reimbursement, and commercial supply readiness.

EU regulatory data and market exclusivity generally follow the "8+2+1" framework:

Protection period Effect
8 years Generic and hybrid applications may be filed using the reference product's data
10 years Generic marketing is generally blocked during the initial data and market-exclusivity period
11 years An additional year may apply for a significant new indication with meaningful clinical benefit

Other protections may apply:

  • Supplementary protection certificates can extend patent protection for eligible products.
  • Pediatric extensions can add six months to certain patent or SPC terms.
  • Orphan medicines generally receive 10 years of market exclusivity, subject to EU rules and possible extension.
  • Paediatric-use marketing authorization products can receive separate regulatory incentives.
  • Advanced therapy medicinal products and biological medicines may have additional regulatory complexity.

A company should separate four dates: patent expiry, regulatory exclusivity expiry, Spanish price-and-reimbursement decision, and expected first commercial supply. The earliest possible legal launch date is not always the practical market-entry date.

What is the patent and litigation environment for medicines in Spain?

Spain has no US-style patent-listing and automatic stay system for generic approvals. Patent disputes are handled through Spanish courts, principally commercial courts, with appeals generally proceeding through the provincial courts and ultimately the Supreme Court on issues of law.

The legal framework includes:

  • European patents validated in Spain.
  • Spanish national patents.
  • Supplementary protection certificates.
  • Patent litigation under the Spanish Patent Act.
  • European patent litigation before Spanish courts.
  • Unitary patent and Unified Patent Court exposure where the relevant patent has unitary effect or the proprietor has selected that system.

Spain's patent system uses the European patent framework, including novelty, inventive step, sufficiency, and pharmaceutical patentability standards. Patent owners may assert compound, formulation, process, dosage, combination, and method-of-treatment claims, subject to applicable European and Spanish law.

Does Spain have Paragraph IV certification?

Spain does not have the US Hatch-Waxman Paragraph IV certification system. A generic company does not use a Spanish equivalent of a Paragraph IV notice to trigger a standardized 30-month stay.

A Spanish generic applicant may still challenge patents by:

  • Filing a revocation or invalidity action.
  • Seeking a declaration of non-infringement.
  • Defending a patent infringement action.
  • Challenging supplementary protection certificates.
  • Relying on the EU Bolar exemption for acts undertaken for regulatory approval.

The Bolar exemption permits certain regulatory-development activities before patent expiry. Commercial manufacture, stocking, and sale remain subject to patent risk unless covered by an applicable exception or license.

What is the Orange Book status of Spain?

Spain has no Orange Book equivalent that performs the US function of listing patents tied to approved products and creating an approval-linked certification system.

The principal public regulatory resources are:

  • AEMPS CIMA: authorized medicines, product information, and regulatory status.
  • AEMPS: safety communications, shortages, inspections, and regulatory decisions.
  • European Medicines Agency: centralized authorizations and European product information.
  • Spanish Patent and Trademark Office: Spanish patent and SPC records.
  • European Patent Office: European patent records.
  • Unified Patent Court: litigation and opt-out information for relevant European patents.

A market-entry review therefore requires a separate patent landscape, regulatory exclusivity analysis, SPC calculation, and court-record search.

What formulations and technologies remain commercially protected?

After compound-patent expiry, branded companies may retain market share through secondary patents and commercial differentiation. Relevant rights include:

  • Extended-release and delayed-release formulations.
  • Fixed-dose combinations.
  • Injectable devices and prefilled syringes.
  • Inhalers and other delivery systems.
  • Depot formulations.
  • Pediatric formulations.
  • Abuse-deterrent or modified-release products.
  • Stability-enhancing excipients.
  • Manufacturing processes and crystallization methods.
  • Dosage regimens and patient-selection claims.
  • Drug-device combinations.

The legal strength of these rights varies. A formulation patent can be commercially important if the formulation is clinically preferred, difficult to design around, or protected by manufacturing know-how. A narrow dosage patent may have less value if physicians can prescribe an alternative regimen or if the generic can avoid the claim.

Hospital products face additional barriers. Sterile manufacturing, device compatibility, cold-chain management, extractables and leachables, container closure, and process validation can delay entry even when the core active-ingredient patent has expired.

How strong is the Spanish patent estate for branded medicines?

Patent strength should be assessed claim by claim rather than by patent count. The most valuable patent assets usually have one or more of the following characteristics:

  1. Broad claims covering the active ingredient or key molecular class.
  2. A valid SPC extending protection into the commercial peak period.
  3. Claims covering the only clinically accepted formulation or delivery device.
  4. Evidence supporting inventive step and unexpected technical effect.
  5. Manufacturing claims that are difficult to design around.
  6. Method-of-use claims linked to the reimbursed indication.
  7. Patent protection in both Spain and major EU markets.

Patent weaknesses commonly arise from:

  • Earlier prior art.
  • Obvious formulation modifications.
  • Insufficient disclosure.
  • Added-matter problems.
  • Invalid dosage or selection claims.
  • Narrow claim scope.
  • Design-around options.
  • A gap between patent expiry and practical commercial relevance.

A company evaluating Spanish entry should model both an "at-risk" launch and a post-expiry launch. The first creates potential price and share advantages but exposes the company to injunctions, damages, inventory loss, and cross-border litigation.

How does Spain regulate medicine pricing and reimbursement?

Spain applies national pricing and reimbursement decisions, but implementation is decentralized. The Interministerial Committee on the Price of Medicines decides whether a medicine is reimbursed and establishes the maximum public price. The Ministry of Health and autonomous communities then influence utilization, procurement, and prescribing.

Key mechanisms include:

  • Reference pricing.
  • Generic substitution and pharmacy dispensing rules.
  • Therapeutic-positioning reports.
  • Hospital tenders.
  • Regional procurement.
  • Managed-entry agreements.
  • Risk-sharing arrangements for selected high-cost medicines.
  • Prescription monitoring and budget controls.

Reference pricing groups medicines considered interchangeable for reimbursement purposes. The system places pressure on the originator and generic price points once a product enters the reference set.

For high-cost medicines, pricing decisions can depend on comparative clinical value, budget impact, unmet need, domestic manufacturing, and supply considerations. The process can delay commercial launch after regulatory approval.

What opportunities exist for branded pharmaceutical companies?

Branded companies have opportunities in areas where clinical differentiation or manufacturing complexity supports premium pricing.

Specialty and hospital medicines

Growth opportunities include oncology, rare diseases, immunology, advanced therapies, hospital anti-infectives, and complex injectables. Market access depends on evidence generation, hospital economics, and regional implementation rather than regulatory approval alone.

Lifecycle management

Originators can extend commercial value through:

  • New indications.
  • Pediatric approvals.
  • Combination products.
  • Long-acting formulations.
  • Devices and digital adherence tools.
  • Local manufacturing or supply commitments.
  • Evidence supporting improved outcomes or reduced total treatment cost.

Lifecycle strategies must account for EU patentability standards and Spanish reimbursement reference pricing.

Local partnerships and licensing

Licensing opportunities are strongest where a Spanish or European partner adds:

  • AEMPS and SNS market-access capability.
  • Hospital tender experience.
  • Distribution infrastructure.
  • Pharmacovigilance and regulatory operations.
  • Manufacturing or packaging capacity.
  • Established relationships with regional health services.

Spain does not have a single public database that captures all private pharmaceutical licensing transactions. Deal terms are often disclosed through company announcements, securities filings, or competition-law filings. Commercial due diligence should distinguish a regulatory license, a marketing authorization transfer, a distribution agreement, and a co-promotion arrangement.

What opportunities exist for generic and biosimilar companies?

Generic companies can target:

  • High-volume molecules approaching patent expiry.
  • Products with limited current supplier competition.
  • Medicines affected by shortages.
  • Hospital injectables.
  • Complex oral dosage forms.
  • Dermatological and ophthalmic products.
  • Authorized generics.
  • Fixed-dose combinations.
  • Regional or national tender opportunities.

Biosimilars are a separate growth segment. Spain has supported biosimilar adoption through hospital procurement, prescribing policies, and cost-containment measures. Interchangeability and substitution practices must be assessed by product and autonomous community. The legal and clinical analysis differs from small-molecule generics because biosimilars require a comparability package, immunogenicity assessment, and a more complex manufacturing and pharmacovigilance system.

Biosimilar developers face competitive pressure from multiple EU manufacturers, tender concentration, reference-product loyalty, and rapid price erosion. Their strongest positions are typically based on reliable supply, manufacturing scale, clinical support, and tender execution rather than patent exclusivity alone.

What regulatory challenges affect market entry?

The principal challenges are:

Challenge Business effect
National reimbursement delay Approval does not guarantee sales
Autonomous-community fragmentation Access and uptake vary by region
Reference pricing Reduces net price after generic entry
Hospital tender concentration Can produce rapid price erosion
Supply obligations Shortages can trigger sanctions or reputational damage
Serialization and traceability Increases operational complexity
Spanish-language packaging Requires localized regulatory execution
Manufacturing inspections Can delay approval or supply
Patent and SPC disputes Can block or increase the cost of launch
Pharmacovigilance Requires local compliance capability

Spain also faces medicine shortages in selected categories. The government and AEMPS have increased scrutiny of supply continuity, stock management, and alternative suppliers. Companies with diversified manufacturing and dependable Spanish supply may gain procurement advantages, but they also assume greater inventory and compliance obligations.

Which companies compete in Spain's branded and generic markets?

Competition includes multinational originators, European generic manufacturers, Spanish laboratory groups, biosimilar developers, hospital specialists, and distributors. Spanish-linked companies with significant pharmaceutical activity include Cinfa, Normon, Kern Pharma, Faes Farma, Laboratorios Farmacéuticos ROVI, Grifols, and Esteve, although their exposure differs by product type and geography.

International competitors include major originator companies and generic groups such as Teva, Sandoz, Viatris, Fresenius Kabi, STADA, and other EU suppliers. The competitive picture is molecule-specific. A company may have a strong national retail presence but limited hospital access, or a strong hospital portfolio but limited community-pharmacy reach.

What generic launch scenarios exist in Spain?

Standard post-expiry launch

The company waits until patent and exclusivity barriers expire, obtains authorization and reimbursement, and enters through community pharmacy or hospital procurement. This is the lowest legal-risk scenario but may face multiple competitors.

At-risk launch

The company launches before final resolution of a patent dispute based on an invalidity or non-infringement position. This can capture early volume but creates injunction and damages exposure.

Tender-led launch

The company prioritizes hospital or institutional contracts. It may accept lower prices in exchange for volume, predictable demand, and rapid share acquisition.

Supply-security launch

The company differentiates through local stock, dual sourcing, or manufacturing capacity in a category affected by shortages. This strategy may improve tender competitiveness but requires sustained supply performance.

Partner-led launch

A foreign company uses a Spanish marketing authorization holder, distributor, or co-commercialization partner. This lowers local infrastructure requirements but reduces margin and control.

What revenue exposure does Spain create for originators?

Originator revenue is exposed at four points:

  1. Loss of regulatory exclusivity.
  2. Patent or SPC expiry.
  3. First generic or biosimilar entry.
  4. Reference-price or tender repricing.

Revenue erosion is usually faster in tendered hospital products and slower in differentiated specialty medicines. The rate depends on the number of entrants, physician substitution, pharmacy incentives, regional policy, supply reliability, and the originator's ability to defend a premium through clinical or device differentiation.

A branded company should model Spain separately from the broader EU because Spanish public prices, tender discounts, regional uptake, and external reference-pricing effects can influence other markets.

What is the outlook for Spain's pharmaceutical market?

The Spanish market offers volume, EU regulatory access, sophisticated clinical infrastructure, and a substantial hospital sector. Its constraints are low public prices, lengthy reimbursement processes, fragmented regional execution, tender pressure, and limited tolerance for weak supply performance.

The strongest opportunities are likely to remain in:

  • Specialty and hospital medicines with clear clinical value.
  • Biosimilars and complex generics.
  • Shortage-sensitive products.
  • Advanced therapies supported by specialized centers.
  • Products with manufacturing or delivery barriers.
  • Licensing arrangements that combine European authorization with local market access.

The weakest opportunities are undifferentiated commodity generics with many existing suppliers, low prices, and no supply or formulation advantage.

Key Takeaways

  • Spain is a high-volume, public-payer pharmaceutical market with strong regional fragmentation.
  • Generics have substantial unit penetration, but value is constrained by reference pricing and tender discounts.
  • Spain has no US-style Orange Book or Paragraph IV system.
  • Generic entry requires separate analysis of EU regulatory exclusivity, Spanish and European patents, SPCs, reimbursement, and procurement.
  • Formulation, device, process, and method-of-use patents can delay or reshape post-compound-expiry competition.
  • Biosimilars offer meaningful opportunities but face tender concentration and rapid price competition.
  • Hospital access and autonomous-community execution are as important as national marketing authorization.
  • Reliable supply, local partnerships, and cost-efficient manufacturing are central commercial advantages.
  • Originators should expect revenue pressure after exclusivity loss unless clinical differentiation, formulation protection, or procurement positioning supports a premium.
  • Generic entrants should prioritize products with limited competition, complex manufacturing, shortage exposure, or strong tender economics.

Frequently Asked Questions

Does Spain allow generic medicines before the reference product patent expires?

Regulatory applications and certain development activities may occur under the EU Bolar exemption, but commercial launch remains subject to enforceable patent and SPC rights.

Is a Spanish generic approval valid across the European Union?

No. A national Spanish authorization is generally limited to Spain. A decentralized, mutual-recognition, or centralized procedure is required for broader EU coverage.

Can Spanish pharmacies automatically substitute biosimilars?

Substitution rules for biological medicines are not identical to those for conventional small-molecule generics. The applicable position depends on Spanish national policy, product classification, and autonomous-community implementation.

How long does Spanish reimbursement take after marketing authorization?

Timing varies by product, therapeutic area, evidence package, price negotiation, and public-policy priorities. Regulatory approval does not create an automatic reimbursement right.

Are Spanish hospital tenders exclusive?

Some tenders select a single supplier, while others award multiple suppliers or framework positions. The risk depends on tender terms, regional procurement rules, and the hospital's purchasing model.

What is the main patent risk for a generic company entering Spain?

The principal risk is infringement of a valid European or Spanish patent, SPC, formulation claim, process claim, or method-of-use claim despite the absence of a Paragraph IV system.

References

  1. Agencia Española de Medicamentos y Productos Sanitarios. (n.d.). CIMA: Centro de Información online de Medicamentos de la AEMPS. https://cima.aemps.es/

  2. Agencia Española de Medicamentos y Productos Sanitarios. (n.d.). Medicines shortages and supply information. https://www.aemps.gob.es/

  3. European Commission. (2004). Directive 2004/27/EC amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union.

  4. European Commission. (2009). Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products. Official Journal of the European Union.

  5. European Commission. (2010). Regulation (EU) No 1235/2010 on pharmacovigilance for medicinal products for human use. Official Journal of the European Union.

  6. European Medicines Agency. (n.d.). Generic and hybrid medicines. https://www.ema.europa.eu/

  7. European Medicines Agency. (n.d.). Biosimilar medicines. https://www.ema.europa.eu/

  8. Ministry of Health, Government of Spain. (n.d.). Pharmaceutical benefits and pricing and reimbursement system. https://www.sanidad.gob.es/

  9. OECD. (2023). Health at a glance 2023: OECD indicators. OECD Publishing. https://doi.org/10.1787/7a7afb35-en

  10. Spanish Patent and Trademark Office. (n.d.). Industrial property information and patent services. https://www.oepm.es/

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.